Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Companies Weigh Offer of Royalties for AIDS Drugs Aimed at Africa

February 16, 2001

Cipla has offered Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, and Boehringer Ingelheim a proposal in which it would gain the rights to sell generic versions of their patented AIDS drugs in Africa in exchange for a 5 percent royalty fee. If the pharmaceutical companies decline Cipla's offer, the generic maker could turn to compulsory licensing provisions to sell its product in Africa without paying royalties. Foreign aid and revenues could drop if countries grant compulsory licensing rights, reducing the likelihood that such action would be taken. Cipla has also offered to sell an array of AIDS drugs to the group Doctors Without Borders at a considerably lower price than what large pharmaceutical companies are willing to charge to underdeveloped countries.


Other CDC News for February 16, 2001

Companies Weigh Offer of Royalties for AIDS Drugs Aimed at Africa

Drug Makers Are Prodded on Cut-Rate AIDS Medications

TB Patient Appeals for Release: Judge Richard Boylston Put Other Action on Hold Until the Appeal Court Rules

Advertisement
Tuberculosis Rise in Britain Linked to Immigration
Hep-C Plagues Cons: 75 percent of Females Infected at Edmonton Institution for Women

Many HIV Patients Report Use of Alternative Meds

World Bank Warns of AIDS Increase in Cameroon

Nigeria Orders Tests on Local Cure for HIV Virus
Study: HAART Less Costly Than Treatment for AIDS


Adapted from:
Wall Street Journal (www.wsj.com)
02/16/01 P. B1; Pearl, Daniel



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 

Tools
 

Advertisement